Search

Displaying results 61 - 70 of 216 in total
  1. Drug

    Cinacalcet

    go.drugbank.com/drugs/DB01012
    ApprovedInvestigational

    Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe.

  2. Drug

    Ergotamine

    go.drugbank.com/drugs/DB00696
    Approved

    A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.

  3. Drug

    Stiripentol

    go.drugbank.com/drugs/DB09118
    ApprovedInvestigational

    [A19739] Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.

  4. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    [A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970.

  5. Drug

    Dimetacrine

    go.drugbank.com/drugs/DB08996
    ApprovedWithdrawn

    Dimetacrine is a tricyclic antidepressant (TCA) with imipramine-like effects used in Europe for the treatment of depression. Dimetacrine is no longer used in Japan.

  6. Drug

    Dienogest

    go.drugbank.com/drugs/DB09123
    ApprovedInvestigational

    It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself. … In Europe, Australia, Malaysia, Singapore and Japan, dienogest single therapy is an approved treatment for endometriosis to alleviate painful symptoms of endometriosis and reduce endometriotic lesions

  7. Drug

    Sumatriptan

    go.drugbank.com/drugs/DB00669
    ApprovedInvestigational

    [L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.

  8. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    L46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European

  9. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients with Alagille syndrome:[L43547] it was granted marketing authorization in Europe

  10. Drug

    Leflunomide

    go.drugbank.com/drugs/DB01097
    ApprovedInvestigational

    Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.